Pharmaceuticals
Scripps Research Institute testing shows Viraleze highly active against UK COVID strain
MELBOURNE, Australia, June 1, 2021 /PRNewswire/ -- Australia's Viraleze anti-COVID nasal spray is active against the highly infectious UK variant of SARS-CoV-2, the virus that causes COVID-19, reducing infectivity of the virus by >98%, it was announced today in a major development for the product...
2021-06-01 17:30
2186
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Agreement Renews Successful Global Collaboration That led to Several Groundbreaking Therapies in Multiple Disease Areas KHK4083 Depletes OX40-Expressing T cells Associated with Atopic Dermatitis and Several Other Inflammatory Diseases Moderate-to-Severe Atopic Dermatitis Affects Nearly 30 Mill...
2021-06-01 16:00
5609
Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China
SAN FRANCISCO and SUZHOU, China, June 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
2021-06-01 08:00
5363
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery
SINGAPORE, May 31, 2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based inSingapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for MLC1501 in traumatic brain injury (TBI). Moleac is dedicated in finding, devel...
2021-05-31 18:33
3061
Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
* HMBD-002 is the only IgG4 isotype anti-VISTA antibody currently in development * HMBD-002 is anticipated to enter a Phase 1 clinical trial in 2021 HOUSTON andSINGAPORE, May 31, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing pr...
2021-05-31 10:00
2353
Nexturn Bio Inc. acquired a 50% stake in RosVivo Therapeutics, Inc.
SEOUL, South Korea, May 30, 2021 /PRNewswire/ -- Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., announced onMay 26th that it had acquired a 50% stake in RosVivo Therapeutics Inc. ("Rosvivo"), an American new drug developer, for about5.5 million U.S. dollars. As a result, Nexturn...
2021-05-30 22:00
5411
CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application
* Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to successfully improve progression-free survival (PFS) in patients with stage III non-small-cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy * Sugemalimab is also t...
2021-05-28 08:10
9143
Viatris Signs Memorandum of Understanding with The Defeat NCD Partnership at the United Nations Institute for Training and Research (UNITAR)
Reveals initial findings of the Viatris sponsored report at a high-level panel discussion GENEVA and DUBAI, United Arab Emirates, May 28, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) and The Defeat-NCD Partnership (DNCD) at The United Nations Institute for Training and Research (UNITAR) toda...
2021-05-28 06:36
9817
ProBioGen and Minapharm Pharmaceuticals incorporate MiGenTra GmbH - A Healthcare Transforming Medicines Company
BERLIN and CAIRO, May 27, 2021 /PRNewswire/ -- ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra" with headquarters inBerlin and access to a site in Cairo, which will house its principal manufacturing plant. The formation of MiGenTra accelerate...
2021-05-27 17:00
3283
Betagenon AB announces new CEO and new Chairman of the Board
STOCKHOLM, May 27, 2021 /PRNewswire/ -- Betagenon AB, a Sweden-based company focused on development of AMPK activator compounds, today announced that James Hall BM, BCh, D.Phil has joined this month as CEO. Dr. Hall brings extensive senior healthcare and life science experience, including 12 yea...
2021-05-27 15:46
1752
Boan Biotech Grants AstraZeneca Exclusive Rights to Promote Boyounuo(R) (Bevacizumab Injection) in Specific County Markets of China
SHANGHAI, May 26, 2021 /PRNewswire/ -- Luye Pharma Group announced today that its holding subsidiary, Boan Biotech, has signed an agreement with AstraZeneca China regarding the promotion rights to the anticancer drugBoyounuo® (Bevacizumab Injection), under which the former will grant to the latte...
2021-05-26 23:03
21105
Merck Accelerates Scale Up of Lipids to Meet Covid-19 Demand
- Introduces new synthetic cholesterol product nine months ahead of schedule - Offers high purity, scalability, and consistent quality - One of a few companies that produces lipids in quantities needed to meet demand for mRNA therapeutics, including Pfizer-BioNTech Covid-19 Vaccine DARMSTADT,...
2021-05-26 20:00
3498
RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19
The two patents protect opaganib and RHB-107 for the treatment of COVID-19 until at least 2041 once granted Enrollment in opaganib's global Phase 2/3 study in hospitalized patients with severe COVID-19 is almost 100% complete RHB-107's ongoing Phase 2/3 study is enrolling U.S. non-hospitalized p...
2021-05-26 19:12
10141
Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)
- Lefamulin was shown to be non-inferior to moxifloxacin, with 76.8% of lefamulin-treated patients meeting the efficacy endpoint of Investigator Assessment of Clinical Response (IACR) at Test of Cure (TOC), compared to 71.4% of patients treated with moxifloxacin - Lefamulin was generally safe an...
2021-05-26 05:00
3250
Nanoform and Celanese Explore Ways to Enhance Drug Delivery
HELSINKI, May 25, 2021 /PRNewswire/ -- Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Celanese Corporation (NYSE: CE), a global specialty materials company, today announced plans to explore the synergies between their respective technologies in the field of nanop...
2021-05-25 21:45
2172
Seegene reports solid results in the first quarter of 2021 with KRW 351.8 billion
* SEEGENE POSTS KRW 193.9 BIL. IN OPERATING PROFIT, UP 388% ON-YEAR * OPERATING PROFIT RATIO AT 55%, DESPITE CONSTANT INVESTMENT IN R&D AND EMPLOYEES SEOUL, South Korea, May 25, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a molecular diagnostics company reported its financial results for th...
2021-05-25 15:33
12384
Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA
HANGZHOU and SHAOXING, China, May 25, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that following the consultation with China National Medical Products Administration (NMPA), the clinical trial application of ASC40 combined with bevacizumab to treat patients with re...
2021-05-25 08:30
3894
Innovent Announces First Patient Dosed in China in the Global Phase 3 Clinical Trial of Pemigatinib as the First-line Treatment of Unresectable or Metastatic Cholangiocarcinoma
SAN FRANCISCO and SUZHOU, China, May 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major dis...
2021-05-25 08:00
12207
Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing
VANCOUVER, British Columbia, May 24, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce thatCharles J. Dunton, MD, has joined BioVaxys as an Advisor to help provide additional scientific support for BVX-0918A,...
2021-05-24 20:00
8000
Akeso's Penpulimab Monoclonal Antibody Submitted BLA in the United States
HONG KONG, May 24, 2021 /PRNewswire/ -- On May 24, 2021, Akeso, Inc. (HKEx: 9926.HK) announced that Penpulimab (research and development code: AK105), an PD-1 monoclonal antibody drug co-developed by the Company with Sino Biopharmaceutical Limited (HKEx: 1177.HK), has submitted a Biologics Licens...
2021-05-24 18:17
3719
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
5883
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
5858
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
5857
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
5819
